Jabrehoo Snares ￥100M in Series B Financing

According to VCBeat, Chinese reproductive genetic service company Peking Jabrehoo Med Tech Co., Ltd ("Jabrehoo") announced the completion of nearly RMB￥100 million Series B+ round of financing. The funds raised will mainly be used for the R&D of innovative products in the reproductive genetic field and promotion of its integrated service platform. The exclusive investor of this round is Apricot Capital, and Haoyue Capital continued to serve as the exclusive financial adviser.

Jabrehoo is the pioneer and leader in providing comprehensive and integrated NGS services for assisted reproductive centers in China. 

In the field of Genetic reproductive technologies, Jabrehoo is currently the largest integrated service platform in China. Since its establishment in 2011, Jabrehoo has been committed to the R&D, transformation and innovation of related products of assisted reproduction, genetics and eugenics, covering equipment, consumables, diagnostic reagents and medical bioinformatics platform. 

Jabrehoo provides NGS-based PGS/PGD solutions for infertility patients and people who prepare for pregnancy, including the detection on the basis of high-throughput sequencing (HTS) technology and related equipment, consumables, management software. In addition, the company is actively promoting the localization of all kinds of tests.

As the first company to introduce NGS technology into PGT in China, Jabrehoo has tested more than 180,000 embryo samples, including more than 43,000 samples for PGT-M. It has the largest single-gene disease S-PGD database in China and can screen more than 510 single-gene diseases.

Jabrehoo's PGT-A kit obtained the special approval of innovative medical devices from NMPA. The company's wholly-owned medical laboratory also obtained the first CAP certification in the field of assisted reproduction in 2019. 

Founded in 2015, Apricot Capital is an investment firm focused on investing in companies in the early and growing stages of the healthcare industry, including biopharmaceuticals, life sciences, medical devices, medical services, and diagnostics.